作者
Ivan Solovic, Martina Sester, Juan J Gomez-Reino, Hans L Rieder, S Ehlers, Heather J Milburn, Beate Kampmann, Bernhard Hellmich, R Groves, Stefan Schreiber, Robert S Wallis, Giovanni Sotgiu, Elisabeth H Schölvinck, Delia Goletti, Jean-Pierre Zellweger, R Diel, Loreto Carmona, Filippo Bartalesi, P Ravn, Aik Bossink, R Duarte, Connie Erkens, J Clark, Giovanni Battista Migliori, Christoph Lange
发表日期
2010/11/1
来源
European Respiratory Journal
卷号
36
期号
5
页码范围
1185-1206
出版商
European Respiratory Society
简介
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB).
Following TNF antagonist therapy, the relative risk for TB is increased up to 25 times, depending on the clinical setting and the TNF antagonist used. Interferon-γ release assays or, as an alternative in individuals without a history of bacille Calmette–Guérin vaccination, tuberculin skin testing is recommended to screen all adult candidates for TNF antagonist treatment for the presence of latent infection with Mycobacterium tuberculosis.
Moreover, paediatric practice suggests concomitant use of both the tuberculin skin test and an interferon-γ release assay …
学术搜索中的文章
I Solovic, M Sester, JJ Gomez-Reino, HL Rieder… - 2010